Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug

MT Newswires Live

04/07

Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.

The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.

Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.

Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2625693726"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625693726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625693726?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625693726","market":"sh","top_or_hot":-1,"title":"Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-07 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625693726","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625693726","pubTimestamp":1775562366,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Precigen  said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"由于复发性呼吸道乳头状瘤病药物的强劲吸收，Precigen预计第一季度收入将超过1800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}